Showing 4771-4780 of 9773 results for "".
- Study Highlights Demographic Factors Linked to Variability in Skin Barrier Functionhttps://practicaldermatology.com/news/study-highlights-demographic-factors-linked-to-variability-in-skin-barrier-function/2486935/Older age, female sex, Black race, and higher BMI were each associated with at least one measure of improved skin barrier function, according to new results published in JID Innovations. Investigators for the cross-sectional analysis of 286 participants fro
- Study: GLP-1 Linked with PASI Reductionshttps://practicaldermatology.com/news/early-evidence-links-glp-1-therapy-to-pasi-reductions/2486929/Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are gaining attention as a potential adjunctive therapy in psoriasis, according to a new review from the National Psoriasis Foundation Medical Board published in JAMA Dermatol
- FDA Flags Six Additional Gel Nail Removers for Banned Chemicalhttps://practicaldermatology.com/news/fda-flags-six-additional-gel-nail-removers-for-banned-chemical/2486820/The US Food and Drug Administration (FDA) has identified six additional cosmetic products marketed as gel nail polish removers that contain methylene chloride, a substance prohibited for use in cosmetics, according to a statement from the agency.</
- Meta-Analysis: Similar AK Clearance With PDT and Cryotherapyhttps://practicaldermatology.com/news/meta-analysis-finds-similar-ak-clearance-with-pdt-and-cryotherapy/2486675/A recent systematic review and meta-analysis suggested comparable efficacy and safety of photodynamic therapy (PDT) and cryotherapy for lesion clearence in actinic keratosis (AK). The analysis, published in the Journal of
- IEC Establishes Global Definitions for AD Disease Control and Remissionhttps://practicaldermatology.com/news/iec-establishes-global-definitions-for-ad-disease-control-and-remission/2486652/A new consensus statement from the International Eczema Council (IEC) proposes standardized definitions for low disease activity (LDA), very low disease activity (vLDA), and remission in atopic dermatitis (AD), addressing what authors noted as a longstanding gap in
- CLL Linked to Higher Skin Cancer Risk and Worse Outcomes in Nationwide Studyhttps://practicaldermatology.com/news/cll-linked-to-higher-skin-cancer-risk-and-worse-outcomes-in-nationwide-study/2486526/Patients with chronic lymphocytic leukemia (CLL) face a significantly elevated risk of developing skin cancer, according to a nationwide Danish cohort study spanning three decades. Study investigators analyzed registry data fr
- Early Inflammatory Signals May Precede Alopecia Areata Diagnosishttps://practicaldermatology.com/news/early-inflammatory-signals-may-precede-alopecia-areata-diagnosis/2486446/Data from a new systematic review presented at the 2026 American Academy of Dermatology Annual Meeting indicated a consistently elevated neutrophil-to-lymphocyte ratio (NLR) in alopecia areata (AA).Investigators used data from PubMed, Embase, and Cochrane
- Nicotinamide Linked to Reduced Melanoma Risk in VA Cohorthttps://practicaldermatology.com/news/nicotinamide-linked-to-reduced-melanoma-risk-in-va-cohort/2486445/Nicotinamide exposure was associated with a 25% reduction in melanoma incidence in a large VA cohort, according to data from a retrospective cohort study presented at the 2026 American Academy of Dermatology Annual Meeting. Investigators analyzed 30,741 pati
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Zasocitinib Demonstrates Biologic-Level Efficacy in Psoriasishttps://practicaldermatology.com/news/zasocitinib-demonstrates-biologic-level-efficacy-in-psoriasis/2486453/Zasocitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, demonstrated rapid and robust efficacy with a consistent safety profile in moderate-to-severe plaque psoriasis, according to Phase 3 LATITUDE-PsO-3001 and LATITUDE-PsO-3002 trial results presented by Melinda Gooderham, MD, MSc, at